Literature DB >> 8980141

Complete amino acid sequence of the A chain of mistletoe lectin I.

M Huguet Soler1, S Stoeva, C Schwamborn, S Wilhelm, T Stiefel, W Voelter.   

Abstract

The complete amino acid sequence of the A chain of mistletoe lectin I was determined via Edman degradation sequencing of the N-terminus and tryptic and endoproteinase Asp-N overlapping fragments, amino acid analysis and MALDI-MS. The data obtained show a great homology with the chains of ribosome-inactivating proteins such as ricin and abrin with 111 (abrin-a) and 103 (ricin-D) amino acid residues conserved, respectively. The knowledge of the primary structure of MLA will have a fundamental impact on elucidating the biological function of medically applied mistletoe lectins on a molecular basis.

Mesh：

Substances：

Year:  1996        PMID： 8980141     DOI： 10.1016/s0014-5793(96)01309-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  6 in total

1.  Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro.

Authors:  U Elsässer-Beile; M Voss; R Schühle; U Wetterauer
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N-end rule pathway.

Authors:  P O Falnes; S Olsnes
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

3.  Unexpected different binding of mistletoe lectins from plant extracts to immobilized lactose and N-acetylgalactosamine.

Authors:  Tibor Hajtò; Fodor Krisztina; Aponyi Ildikò; Pallai Zsolt; Balogh Pèter; Németh Pèter; Perjési Pàl
Journal:  Anal Chem Insights       Date:  2007-09-17

4.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

5.  Specific refolding pathway of viscumin A chain in membrane-like medium reveals a possible mechanism of toxin entry into cell.

Authors:  Pavel E Volynsky; Dmitry E Nolde; Galina S Zakharova; Rex A Palmer; Alexander G Tonevitsky; Roman G Efremov
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

6.  Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine.

Authors:  Tibor Hajtó; Krisztina Fodor; Pál Perjési; Pèter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-09       Impact factor: 2.629
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.